Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
34 hedge funds and large institutions have $32.3M invested in Zynerba Pharmaceuticals, Inc in 2016 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 2 closing their positions.
12,025% more call options, than puts
Call options by funds: $3.4M | Put options by funds: $28K
650% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 2
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
62% more funds holding
Funds holding: 21 → 34 (+13)
23% more capital invested
Capital invested by funds: $26.3M → $32.3M (+$6.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$962K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$794K |
| 3 |
CCMU
Cheyne Capital Management (UK)
London,
United Kingdom
|
+$673K |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$626K |
| 5 |
RIL
Rothschild Investment LLC
Chicago,
Illinois
|
+$315K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$2.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$361K |
| 3 |
AAM
Auxier Asset Management
Aurora,
Oregon
|
-$241K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$225K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$82.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GT
26
Glenmede Trust
Philadelphia,
Pennsylvania
| $7K | +$6.73K | +500 | New |
|
|
MWM
27
MinichMacGregor Wealth Management
Saratoga Springs,
New York
| $6K | +$5.39K | +400 | New |
|
28
Creative Planning
Overland Park,
Kansas
| $5K | +$4.32K | +321 | New |
|
|
CG
29
Cutler Group
San Francisco,
California
| $3K | +$1.35K | +100 | +100% |
|
|
LTFS
30
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$1.35K | +100 | New |
|
|
AIM
32
Acrospire Investment Management
Chicago,
Illinois
| $2K | +$1.41K | +105 | New |
|
|
FPF
33
FNY Partners Fund
New York
| $47 | +$40.4K | +3,000 | New |
|
34
BNP Paribas Financial Markets
Paris,
France
| $16 | – | – | – |
|
|
EA
35
Emerald Advisers
Leola,
Pennsylvania
| – | -$2.3M | -176,514 | Closed |
|
|
36
Citadel Advisors
Miami,
Florida
| – | -$225K | -16,677 | Closed |
|
ZYNE Hedge Fund Activity: Q4 2016 in Review
34 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q4 2016, worth a combined $32.3M — up 23% from $26.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ZYNE positions and 2 closed out — a net gain of 13 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $962K. The largest seller was Emerald Advisers, exiting entirely with an estimated $2.3M sold.
- 34 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q4 2016, up from 21 in Q3 2016.
- Funds reported $32.3M of Zynerba Pharmaceuticals, Inc stock for Q4 2016, up 23% quarter-over-quarter.
- 15 funds opened new Zynerba Pharmaceuticals, Inc positions in Q4 2016 and 2 closed out, a net change of +13 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q4 2016 was J. Goldman & Co, an estimated $962K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q4 2016 was Emerald Advisers, an estimated $2.3M sold.
Based on aggregated 13F filings for Q4 2016.